Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.

Autor: DiNardo, Courtney D.1 (AUTHOR) cdinardo@mdanderson.org, Olin, Rebecca2 (AUTHOR), Wang, Eunice S.3 (AUTHOR), Skikne, Barry4 (AUTHOR), Rosenthal, Joseph5 (AUTHOR), Kumar, Prasanna6 (AUTHOR), Sumi, Hiroyuki7 (AUTHOR), Hizukuri, Yoshiyuki7 (AUTHOR), Hong, Ying6 (AUTHOR), Patel, Parul6 (AUTHOR), Seki, Takahiko6 (AUTHOR), Duan, Tao6 (AUTHOR), Lesegretain, Arnaud6 (AUTHOR), Andreeff, Michael1 (AUTHOR)
Zdroj: Cancer Medicine. Jul2024, Vol. 13 Issue 14, p1-12. 12p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje